RU2418004C2 - Модуляторы активатора фактора роста гепатоцитов - Google Patents

Модуляторы активатора фактора роста гепатоцитов Download PDF

Info

Publication number
RU2418004C2
RU2418004C2 RU2007116806/10A RU2007116806A RU2418004C2 RU 2418004 C2 RU2418004 C2 RU 2418004C2 RU 2007116806/10 A RU2007116806/10 A RU 2007116806/10A RU 2007116806 A RU2007116806 A RU 2007116806A RU 2418004 C2 RU2418004 C2 RU 2418004C2
Authority
RU
Russia
Prior art keywords
sequence
seq
cdr
antibody
hgfa
Prior art date
Application number
RU2007116806/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2007116806A (ru
Inventor
Дэниел К. КИРКХОФЕР (US)
Дэниел К. КИРКХОФЕР
Ян ВУ (US)
Ян Ву
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2007116806A publication Critical patent/RU2007116806A/ru
Application granted granted Critical
Publication of RU2418004C2 publication Critical patent/RU2418004C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2007116806/10A 2004-10-04 2005-10-03 Модуляторы активатора фактора роста гепатоцитов RU2418004C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61565704P 2004-10-04 2004-10-04
US60/615,657 2004-10-04

Publications (2)

Publication Number Publication Date
RU2007116806A RU2007116806A (ru) 2008-11-10
RU2418004C2 true RU2418004C2 (ru) 2011-05-10

Family

ID=36148972

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007116806/10A RU2418004C2 (ru) 2004-10-04 2005-10-03 Модуляторы активатора фактора роста гепатоцитов

Country Status (15)

Country Link
US (4) US20060147451A1 (OSRAM)
EP (1) EP1809673B1 (OSRAM)
JP (2) JP4937127B2 (OSRAM)
KR (1) KR101252306B1 (OSRAM)
CN (1) CN101035810B (OSRAM)
AU (1) AU2005294146B2 (OSRAM)
BR (1) BRPI0515670A (OSRAM)
CA (1) CA2577598C (OSRAM)
ES (1) ES2398528T3 (OSRAM)
IL (1) IL181450A0 (OSRAM)
NO (1) NO20072302L (OSRAM)
NZ (1) NZ553327A (OSRAM)
RU (1) RU2418004C2 (OSRAM)
WO (1) WO2006042173A2 (OSRAM)
ZA (1) ZA200701789B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147451A1 (en) 2004-10-04 2006-07-06 Genentech, Inc. Modulators of hepatocyte growth factor activator
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
CN101652389A (zh) * 2007-02-09 2010-02-17 健泰科生物技术公司 抗robo4抗体及其用途
EP3130607B1 (en) 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
BR112012009245A2 (pt) * 2009-10-19 2019-09-24 Genentech Inc ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
EP2491059B1 (en) 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2023172863A1 (en) * 2022-03-07 2023-09-14 Elixiron Immunotherapeutics (hong Kong) Limited Anti-cd36 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213302B1 (en) * 2000-12-05 2007-03-07 Mitsubishi Chemical Corporation Specific antibody directed to active but not inactive hepatocyte growth factor activator (HGFA)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
CA2102463A1 (en) * 1992-11-05 1994-05-06 Mitsubishi Chemical Corporation Protein and gene encoding said protein
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
JP4090236B2 (ja) * 2000-12-05 2008-05-28 三菱化学株式会社 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
US20060147451A1 (en) 2004-10-04 2006-07-06 Genentech, Inc. Modulators of hepatocyte growth factor activator

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1213302B1 (en) * 2000-12-05 2007-03-07 Mitsubishi Chemical Corporation Specific antibody directed to active but not inactive hepatocyte growth factor activator (HGFA)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
КАТАОКА Н., ет al. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res., 60(21) 01.11.2000, с. 6148-6159. MIYAZAWA К., et al. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J. Biol. Chem., 271(7), 16.02.1996, с. 3615-3618. *

Also Published As

Publication number Publication date
EP1809673A2 (en) 2007-07-25
KR101252306B1 (ko) 2013-04-08
EP1809673B1 (en) 2012-11-28
IL181450A0 (en) 2007-07-04
US20090047291A1 (en) 2009-02-19
JP2012025752A (ja) 2012-02-09
KR20070102470A (ko) 2007-10-18
US20110098449A1 (en) 2011-04-28
US7825221B2 (en) 2010-11-02
US20130217862A1 (en) 2013-08-22
CA2577598C (en) 2016-09-20
JP4937127B2 (ja) 2012-05-23
CN101035810A (zh) 2007-09-12
CA2577598A1 (en) 2006-04-20
NO20072302L (no) 2007-06-28
NZ553327A (en) 2010-02-26
HK1105006A1 (en) 2008-02-01
CN101035810B (zh) 2011-04-06
JP2008515918A (ja) 2008-05-15
US8969528B2 (en) 2015-03-03
AU2005294146A1 (en) 2006-04-20
RU2007116806A (ru) 2008-11-10
ES2398528T3 (es) 2013-03-19
JP5554298B2 (ja) 2014-07-23
AU2005294146B2 (en) 2011-09-15
BRPI0515670A (pt) 2008-07-29
WO2006042173A3 (en) 2006-08-17
WO2006042173A2 (en) 2006-04-20
US8399629B2 (en) 2013-03-19
US20060147451A1 (en) 2006-07-06
ZA200701789B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
JP5554298B2 (ja) 肝細胞成長因子活性化物質のモジュレータ
JP5902130B2 (ja) 抗エフリンｂ２抗体とその使用方法
KR20100100914A (ko) 항―ｖｅｇｆ 항체
KR101038633B1 (ko) Ｅｇｆｌ７에 대한 항체 및 그의 사용 방법
BRPI0706840A2 (pt) anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo
US8759491B2 (en) Modulators of hepatocyte growth factor activator
AU2011254032B2 (en) Modulators of Hepatocyte Growth Factor Activator
TWI429655B (zh) 抗egfl7抗體、包含其之組合物、編碼其之多核苷酸及其製造及使用方法
HK1105006B (en) Modulators of hepatocyte growth factor activator
MX2007003832A (en) Modulators of hepatocyte growth factor activator
HK1178180B (en) Modulators of hepatocyte growth factor activator
HK1187352B (en) Anti-ephrinb2 antibodies and methods using same
HK1171764A (en) Antibodies to egfl7 and methods for their use

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171004